Brian Armstrong, the billionaire behind cryptocurrency giant Coinbase, isn’t just dreaming of digital revolutions anymore—he now has his sights set on something even more radical: gene-edited human embryos. In a bold move that could reshape the future of reproduction and genetics, Armstrong publicly announced plans on June 2 to build a startup focused on embryo editing, aiming to “treat disease” by correcting faulty genes before birth.
If realized, his venture would become the first major commercial push in the United States to turn CRISPR technology from lab-based theory into reproductive reality. And while some scientists are wary, others say it’s exactly what the field needs.
Armstrong’s proposal enters a space still haunted by controversy. In 2018, the world learned of the first genetically edited babies, born in secret in China—a shocking act that triggered international outrage and led to prison time for the scientist involved. Since then, countries including the U.S. have banned gene-edited births.
But Armstrong’s interest suggests the tide may be shifting. He’s not quietly bankrolling rogue experiments—he’s going public. And according to researchers like Columbia University’s Dieter Egli, who has briefed Armstrong’s team, the billionaire may be arriving at a turning point in the science.
“We know much better now what to do,” Egli says. “It doesn’t mean the work is all done, but it’s a very different game now—entirely different.”
That difference lies in new editing tools like base editing, a technique that can swap out a single DNA letter without breaking the genetic code. Unlike earlier CRISPR methods—which often caused dangerous DNA cuts—this newer approach is more precise and less likely to cause unintended mutations.
Armstrong isn’t diving into this alone. He and his venture partner, Blake Byers, a self-declared enthusiast of “immortality” science, have been quietly laying the groundwork. In December, they hosted an invitation-only “forbidden technologies” dinner, inviting researchers working on everything from artificial wombs to advanced IVF to embryo editing.
Among the guests were researchers like Stepan Jerabek, a postdoc from Egli’s lab testing base editing in embryos, and Lucas Harrington, a gene-editing scientist who trained with CRISPR pioneer Jennifer Doudna. Harrington confirmed that his group is also exploring a startup dedicated to embryo editing.
The potential benefits are immense, in theory. Gene editing could correct harmful mutations that cause devastating childhood conditions before the baby is even born. Instead of treating the disease after it appears, the approach could prevent it entirely.
“You fix the text before you print the book,” Egli explained.
Yet, critics point out that many of these mutations can already be avoided by selecting healthy embryos during IVF. That leaves the door open to a more controversial use: not just preventing disease, but enhancing traits like disease resistance—or intelligence.
And that’s where things get murky. Some scientists fear a return to eugenics, the discredited idea of controlling human evolution through selective breeding. Just last week, multiple biotech groups called for a 10-year global moratorium on heritable gene editing, warning of “long-term risks with unknown consequences.”
But Harrington counters that bans don’t stop progress—they just push it underground.
Despite its stigma, many researchers say gene editing of embryos is easier, cheaper, and potentially more effective than treating diseases later in life. For example, the only approved gene-editing therapy—used for sickle-cell disease—costs over $2 million. Editing an embryo early, when it’s just a bundle of cells, could be faster and cheaper, ensuring the fix appears in every cell of the body.
But achieving that level of safety and precision will take massive effort—engineering, testing, and scrutiny that only a well-funded, dedicated company could provide.
While the scientific and ethical stakes are huge, the human element is what truly defines this story. What kind of world would we enter if parents could edit their children’s genes? Who gets access? Who decides what traits are desirable?
Armstrong hasn’t publicly responded to questions about the deeper goals of his potential startup. But his openness about the idea has already ignited a conversation that scientists say the world desperately needs to have.
As gene editing tools grow more precise, the question is no longer whether we can rewrite the genetic future, but whether we should. And if so, who leads the way: governments, scientists, or tech billionaires?
For now, one thing is clear: the future of human reproduction may be closer than we think, and it’s arriving not from a government lab, but from Silicon Valley.
Copyright @smorescience. All rights reserved. Do not copy, cite, publish, or distribute this content without permission.
